Gene · 3078
Papers1,634
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
201 to 220 of 1,634
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Comparative proteomics analyses of whey proteins from breastmilk collected from two ethnic groups in northeast China. | Food Chem X | 2023 | 36845516 | PubTator, text mining | PubMed |
| An ex vivo test to investigate genetic factors conferring susceptibility to atypical haemolytic uremic syndrome. | Front Immunol | 2023 | 36845135 | PubTator, text mining | PubMed |
| Pathways for Cardioprotection in Perspective: Focus on Remote Conditioning and Extracellular Vesicles. | Biology (Basel) | 2023 | 36829584 | PubTator, text mining | PubMed |
| Metformin attenuates fibroblast activation during pulmonary fibrosis by targeting S100A4 via AMPK-STAT3 axis. | Front Pharmacol | 2023 | 36817136 | PubTator, text mining | PubMed |
| Targeted genotyping of COVID-19 patients reveals a signature of complement C3 and factor B coding SNPs associated with severe infection. | Immunobiology | 2023 | 36805858 | PubTator, text mining | PubMed |
| The Sertoli Cell Complement Signature: A Suspected Mechanism in Xenograft Survival. | Int J Mol Sci | 2023 | 36768217 | PubTator, text mining | PubMed |
| Editorial: Complement: Latest developments regarding structure, mechanism, and connections to other proteolytic pathways. | Front Immunol | 2023 | 36761776 | PubTator, text mining | PubMed |
| CFH-CFHR1 hybrid genes in two cases of atypical hemolytic uremic syndrome. | J Hum Genet | 2023 | 36755127 | PubTator, text mining | PubMed |
| Cyclohexane-1,3-dione Derivatives as Future Therapeutic Agents for NSCLC: QSAR Modeling, In Silico ADME-Tox Properties, and Structure-Based Drug Designing Approach. | ACS Omega | 2023 | 36743017 | PubTator, text mining | PubMed |
| Multi-region sampling with paired sample sequencing analyses reveals sub-groups of patients with novel patient-specific dysregulation in Hepatocellular Carcinoma. | BMC Cancer | 2023 | 36737737 | PubTator, text mining | PubMed |
| Exploring the hub mechanisms of ischemic stroke based on protein-protein interaction networks related to ischemic stroke and inflammatory bowel disease. | Sci Rep | 2023 | 36720935 | PubTator, text mining | PubMed |
| Trimeric, APC-Targeted Subunit Vaccines Protect Mice against Seasonal and Pandemic Influenza. | J Virol | 2023 | 36719241 | PubTator, text mining | PubMed |
| The Use of Eculizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in an Academic Hematology Center. | Perm J | 2023 | 36718583 | PubTator, text mining | PubMed |
| Factor H autoantibodies contribute to complement dysregulation in multisystem inflammatory syndrome in children (MIS-C). | Am J Hematol | 2023 | 36715424 | PubTator, text mining | PubMed |
| Renal Genetics Clinic: 3-Year Experience in the Cleveland Clinic. | Kidney Med | 2023 | 36712315 | PubTator, text mining | PubMed |
| Chemotherapy-Associated Thrombotic Microangiopathy. | Kidney360 | 2023 | 36706238 | PubTator, text mining | PubMed |
| Phenome-wide Mendelian randomisation analysis identifies causal factors for age-related macular degeneration. | Elife | 2023 | 36705323 | PubTator, text mining | PubMed |
| IgA Nephropathy: Current Understanding and Perspectives on Pathogenesis and Targeted Treatment. | Diagnostics (Basel) | 2023 | 36673113 | PubTator, text mining | PubMed |
| Recent Progress in Nanomaterial-Based Biosensors and Theranostic Nanomedicine for Bladder Cancer. | Biosensors (Basel) | 2023 | 36671940 | PubTator, text mining | PubMed |
| Clinical value of the renal pathologic scoring system in complement-mediated thrombotic microangiopathy. | Ren Fail | 2023 | 36648027 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/3078/papers?page=11